Oral Capecitabine Achieves Response in Metastatic Eccrine Carcinoma
The low prevalence rate and limited literature on eccrine carcinoma (EC) pose a challenge to properly diagnosing and treating this rare malignancy. EC lesions tend to present similarly to other cutaneous neoplasms and dermatitis-like conditions. Efficacious treatment guidelines have not been establi...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2018/7127048 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553356948668416 |
|---|---|
| author | Kristian Larson Hani M. Babiker Andrew Kovoor Joy Liau Jordan Eldersveld Emad Elquza |
| author_facet | Kristian Larson Hani M. Babiker Andrew Kovoor Joy Liau Jordan Eldersveld Emad Elquza |
| author_sort | Kristian Larson |
| collection | DOAJ |
| description | The low prevalence rate and limited literature on eccrine carcinoma (EC) pose a challenge to properly diagnosing and treating this rare malignancy. EC lesions tend to present similarly to other cutaneous neoplasms and dermatitis-like conditions. Efficacious treatment guidelines have not been established for patients diagnosed with EC, and few treatment regimens have demonstrated clinical benefit. Due to the high metastatic potential of EC, recognizing the clinical presentation, properly diagnosing, and utilizing beneficial treatment options are important for managing this disease. We report a case of a 66-year-old female who presented with lesions that her primary care provider misdiagnosed as basal cell carcinoma. The disease responded poorly to taxane- and platinum-based chemotherapies as well as an isolated limb perfusion of an alkylating agent. However, continuous dosing of oral capecitabine achieved an 18-month period of progression free survival (PFS) and ameliorated quality of life. We wish to highlight this rare disease and discuss presentation, diagnosis, and management as it is most often misdiagnosed leading to advanced metastatic disease when patients present to the oncologist. In addition, it is crucial to study and report potentially efficacious regimens considering the lack of clinical trials in this disease. |
| format | Article |
| id | doaj-art-c530d867e848408d83c1151aa10b5444 |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-c530d867e848408d83c1151aa10b54442025-02-03T05:54:16ZengWileyCase Reports in Oncological Medicine2090-67062090-67142018-01-01201810.1155/2018/71270487127048Oral Capecitabine Achieves Response in Metastatic Eccrine CarcinomaKristian Larson0Hani M. Babiker1Andrew Kovoor2Joy Liau3Jordan Eldersveld4Emad Elquza5Early Phase Clinical Trial Program, The University of Arizona Cancer Center, 1515 N. Campbell Ave., Tucson, AZ 85724, USAEarly Phase Clinical Trial Program, The University of Arizona Cancer Center, 1515 N. Campbell Ave., Tucson, AZ 85724, USADivision of Hematology and Oncology, University of Arizona College of Medicine, 1515 N. Campbell Ave., Tucson, AZ 85724, USADepartment of Medical Imaging, University of Arizona, 1501 N. Campbell Ave., Tucson, AZ 85712, USADepartment of Pathology, University of Arizona, 1501 N. Campbell Ave., Tucson, AZ 85712, USAEarly Phase Clinical Trial Program, The University of Arizona Cancer Center, 1515 N. Campbell Ave., Tucson, AZ 85724, USAThe low prevalence rate and limited literature on eccrine carcinoma (EC) pose a challenge to properly diagnosing and treating this rare malignancy. EC lesions tend to present similarly to other cutaneous neoplasms and dermatitis-like conditions. Efficacious treatment guidelines have not been established for patients diagnosed with EC, and few treatment regimens have demonstrated clinical benefit. Due to the high metastatic potential of EC, recognizing the clinical presentation, properly diagnosing, and utilizing beneficial treatment options are important for managing this disease. We report a case of a 66-year-old female who presented with lesions that her primary care provider misdiagnosed as basal cell carcinoma. The disease responded poorly to taxane- and platinum-based chemotherapies as well as an isolated limb perfusion of an alkylating agent. However, continuous dosing of oral capecitabine achieved an 18-month period of progression free survival (PFS) and ameliorated quality of life. We wish to highlight this rare disease and discuss presentation, diagnosis, and management as it is most often misdiagnosed leading to advanced metastatic disease when patients present to the oncologist. In addition, it is crucial to study and report potentially efficacious regimens considering the lack of clinical trials in this disease.http://dx.doi.org/10.1155/2018/7127048 |
| spellingShingle | Kristian Larson Hani M. Babiker Andrew Kovoor Joy Liau Jordan Eldersveld Emad Elquza Oral Capecitabine Achieves Response in Metastatic Eccrine Carcinoma Case Reports in Oncological Medicine |
| title | Oral Capecitabine Achieves Response in Metastatic Eccrine Carcinoma |
| title_full | Oral Capecitabine Achieves Response in Metastatic Eccrine Carcinoma |
| title_fullStr | Oral Capecitabine Achieves Response in Metastatic Eccrine Carcinoma |
| title_full_unstemmed | Oral Capecitabine Achieves Response in Metastatic Eccrine Carcinoma |
| title_short | Oral Capecitabine Achieves Response in Metastatic Eccrine Carcinoma |
| title_sort | oral capecitabine achieves response in metastatic eccrine carcinoma |
| url | http://dx.doi.org/10.1155/2018/7127048 |
| work_keys_str_mv | AT kristianlarson oralcapecitabineachievesresponseinmetastaticeccrinecarcinoma AT hanimbabiker oralcapecitabineachievesresponseinmetastaticeccrinecarcinoma AT andrewkovoor oralcapecitabineachievesresponseinmetastaticeccrinecarcinoma AT joyliau oralcapecitabineachievesresponseinmetastaticeccrinecarcinoma AT jordaneldersveld oralcapecitabineachievesresponseinmetastaticeccrinecarcinoma AT emadelquza oralcapecitabineachievesresponseinmetastaticeccrinecarcinoma |